|
7/20/2010
CEO of Stemline invited to present at Drug Discovery and Development Conference Aug. 4, 2010 |
|
3/21/2010
Stemline CEO invited to speak at Cancer Stem Cell conference (Mar. 24-25, 2010) |
|
12/4/2009
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) |
|
11/30/2009
Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center |
|
7/30/2009
Stemline CEO is invited speaker at New Frontiers in Cancer Drug Development (Aug. 4-6, 2009) |
|
2/5/2009
Nature BioCentury (SciBx) interviews Stemline’s Director of Operations in Notch signaling article |
|
4/9/2008
Stemline Therapeutics raises $12.5 million |
|
12/10/2007
L.A. Times cites Stemline and CEO |
|
5/10/2007
Stemline and CEO cited in Oncology Times article |
|
5/7/2007
Stemline CEO is a panelist and speaker at BIO 2007 |
|
3/7/2007
Stemline Therapeutics In-Licenses Phase I Oncology Compound |
|
12/7/2006
Stemline CEO is an invited speaker at the New York Academy of Sciences |
|
9/29/2006
Stemline is awarded a National Institutes of Health STTR grant |
|
1/20/2005
Stemline is cited in New Scientist article |
|
1/18/2005
Stemline is cited in BBC article entitled “Malignant cells targeted in study” |
|
1/17/2005
Stemline licenses high throughput drug discovery technology from University of Cambridge |
